Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

NCT01950819 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

2037

Enrollment

INDUSTRY

Sponsor class

Conditions

End Stage Renal Disease (ESRD)
Chronic Kidney Disease (CKD)
Hemodialysis
Renal Replacement Therapy
Renal Transplantation

Interventions

BIOLOGICAL: Induction therapy
DRUG: Corticosteroids
DRUG: EVR+rCNI
DRUG: MPA+sCNI

Sponsor

Novartis Pharmaceuticals